

## Separation of Doxapram Hydrochloride and its Organic Impurities per USP Monograph

Waleed Afaq, Zeshan Aqeel, and Bryan Tackett, PhD  
Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501, USA

### Overview


Doxapram Hydrochloride is a respiratory stimulant that has an inhibitory effect on myocardial IK1 potassium channels. The development of a quick and efficient analysis of Doxapram Hydrochloride and its related organic impurities is of interest for drug manufacturers. In this application note, we report the separation of Doxapram Hydrochloride and its related organic impurities using a Luna Omega 3  $\mu\text{m}$  PS C18 column and a Kinetex 2.6  $\mu\text{m}$  PS C18 column according to the USP monograph for Doxapram Hydrochloride.

System suitability per USP Monograph for the Doxapram Hydrochloride Assay is a tailing factor no more than (NMT) 2.0 for Doxapram Hydrochloride and a percent relative standard deviation (%RSD) of NMT 0.73 % for Doxapram Hydrochloride. All system suitability requirements for Doxapram Hydrochloride Assay were met with the Waters XSelect CSH C18 and the Luna Omega PS C18 columns. The Kinetex PS C18 column met the requirement of %RSD NMT 0.73 % but did not meet the requirement for tailing factor NMT than 2.0 for system suitability (Figure 2).

System suitability per USP Monograph for the Doxapram Hydrochloride Organic Impurities is a resolution no less than 5.0 between Doxapram Hydrochloride and Doxapram Related Compound B, as well as a %RSD NMT 5.0 %. These requirements for System Suitability for Organic Impurities were met for each of the columns tested (Figure 3 and 4).

All solutions were prepared as indicated in the USP Monograph for Doxapram Hydrochloride. USP Doxapram Hydrochloride RS (Catalog No. 1225000) and USP Doxapram Related Compound B RS (Catalog No. 1225022) were purchased from USP.

Figure 1. Doxapram Hydrochloride



### LC-UV Conditions

**Column:** Luna™ Omega 3  $\mu\text{m}$  PS C18 (00B-4758-E0)  
Kinetex™ 2.6  $\mu\text{m}$  PS C18 (00B-4780-E0)  
Waters® 2.5  $\mu\text{m}$  XSelect® CSH C18

**Dimension:** 50 X 4.6 mm

**Mobile Phase:** A: 0.01 % Trifluoroacetic Acid in Water  
B: 0.01 % Trifluoroacetic Acid in Acetonitrile

**Flow Rate:** 1 mL/min

Gradient: Time (min)	%B
0	10
20	50
25	50
25.1	10
30	10

**Injection Volume:** 5  $\mu\text{L}$

**Temperature:** 35 °C

**Detector:** UV @ 220 nm

**System:** Agilent® 1260 Binary UHPLC




*NOTE:* The forthcoming revision to USP General Chapter <621> will become official December 1<sup>st</sup>, 2022, and adjustments to column dimensions for gradient methods will be allowed provided that the L/dp ratio remains constant or within the range between -25 % to +50 % of the prescribed L/dp ratio indicated in the monograph. In this monograph, the indicated column length was 50 mm, and the particle size was 2.5  $\mu\text{m}$ ; therefore, the Luna Omega 3  $\mu\text{m}$  and Kinetex 2.6  $\mu\text{m}$  columns used here would be an allowable adjustment.

Table 1. Preparation of Solutions

Solution	Composition
Diluent	Acetonitrile/Water (30:70, v/v)
Standard Solution – Assay	0.2 mg/mL of USP Doxapram Hydrochloride RS in Diluent
Standard Solution – Organic Impurities	0.004 mg/mL each of USP Doxapram Hydrochloride RS and USP Doxapram Related Compound B RS in Diluent
System Suitability Solution – Organic Impurities	2 mg/mL of USP Doxapram Hydrochloride RS and 0.04 mg/mL of USP Doxapram Related Compound B RS in Diluent






**Figure 2. Standard Solution – Assay**



Peak No.	Analyte	Waters 2.5 µm XSelect CSH C18		Luna Omega 3 µm PS C18		Kinetex 2.6 µm PS C18	
		Tailing Factor	Area %RSD	Tailing Factor	Area %RSD	Tailing Factor	Area %RSD
1	Doxapram Hydrochloride	1.769	0.166	1.569	0.026	2.849	0.097
N = 5 Injections							






**Figure 3.** Standard Solution – Organic Impurities



Peak No.	Analyte	Waters 2.5 µm XSelect CSH C18 Area %RSD	Luna Omega 3 µm PS C18 Area %RSD	Kinetex 2.6 µm PS C18 Area %RSD
1	Doxapram Related Compound B	0.974	0.739	0.431
2	Doxapram Hydrochloride	0.272	0.475	0.758
N = 6 Injections				



**Figure 4.** System Suitability Solution – Organic Impurities



Peak No.	Analyte	Waters 2.5 µm XSelect CSH C18 Resolution	Luna Omega 3 µm PS C18 Resolution	Kinetex 2.6 µm PS C18 Resolution
1	Doxapram Related Compound B	3.63	3.30	1.54
2	Doxapram Hydrochloride			
N = 3 Injections				



**Need a different column size or sample preparation format?**

No problem! We have a majority of our available dimensions up on [www.phenomenex.com](http://www.phenomenex.com), but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal [www.phenomenex.com/Chat](http://www.phenomenex.com/Chat).

**Australia**

t: +61 (0)2-9428-6444  
auinfo@phenomenex.com

**Austria**

t: +43 (0)1-319-1301  
anfrage@phenomenex.com

**Belgium**

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
beinfo@phenomenex.com

**Canada**

t: +1 (800) 543-3681  
info@phenomenex.com

**China**

t: +86 400-606-8099  
cninfo@phenomenex.com

**Czech Republic**

t: +420 272 017 077  
cz-info@phenomenex.com

**Denmark**

t: +45 4824 8048  
nordicinfo@phenomenex.com

**Finland**

t: +358 (0)9 4789 0063  
nordicinfo@phenomenex.com

**France**

t: +33 (0)1 30 09 21 10  
franceinfo@phenomenex.com

**Germany**

t: +49 (0)6021-58830-0  
anfrage@phenomenex.com

**Hong Kong**

t: +852 6012 8162  
hkinfo@phenomenex.com

**India**

t: +91 (0)40-3012 2400  
indiainfo@phenomenex.com

**Indonesia**

t: +62 21 5010 9707  
indoinfo@phenomenex.com

**Ireland**

t: +353 (0)1 247 5405  
eirinfo@phenomenex.com

**Italy**

t: +39 051 6327511  
italiainfo@phenomenex.com

**Japan**

t: +81 (0) 120-149-262  
jpinfo@phenomenex.com

**Luxembourg**

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**Mexico**

t: 01-800-844-5226  
tecnicomx@phenomenex.com

**The Netherlands**

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**New Zealand**

t: +64 (0)9-4780951  
nzinfo@phenomenex.com

**Norway**

t: +47 810 02 005  
nordicinfo@phenomenex.com

**Poland**

t: +48 22 104 21 72  
pl-info@phenomenex.com

**Portugal**

t: +351 221 450 488  
ptinfo@phenomenex.com

**Singapore**

t: +65 800-852-3944  
sginfo@phenomenex.com

**Slovakia**

t: +420 272 017 077  
sk-info@phenomenex.com

**Spain**

t: +34 91-413-8613  
espinfo@phenomenex.com

**Sweden**

t: +46 (0)8 611 6950  
nordicinfo@phenomenex.com

**Switzerland**

t: +41 (0)61 692 20 20  
swissinfo@phenomenex.com

**Taiwan**

t: +886 (0) 0801-49-1246  
twinfo@phenomenex.com

**Thailand**

t: +66 (0) 2 566 0287  
thaiinfo@phenomenex.com

**United Kingdom**

t: +44 (0)1625-501367  
ukinfo@phenomenex.com

**USA**

t: +1 (310) 212-0555  
info@phenomenex.com

**☉ All other countries/regions**

**Corporate Office USA**  
t: +1 (310) 212-0555  
info@phenomenex.com

**www.phenomenex.com**

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)

**BE-HAPPY™**  
GUARANTEE

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

[www.phenomenex.com/behappy](http://www.phenomenex.com/behappy)

**Terms and Conditions**

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

**Trademarks**

Luna, Kinetex and BE-HAPPY are trademarks of Phenomenex. Waters and XSelect are registered trademarks of Waters Technologies Corporation. Agilent is a registered trademark of Agilent Technologies, Inc.

**Disclaimer**

Comparative separations may not be representative of all applications  
Phenomenex is in no way affiliated with Waters Technologies Corporation or Agilent Technologies, Inc.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2022 Phenomenex, Inc. All rights reserved.

